
    
      This Phase 2 study will be performed by 1 site in Canada. The total duration of study
      participation for each patient is at least 18 weeks and comprises 6 study visits.

      Patients who choose to participate in the extension study will be in the study for a total of
      up to 32 weeks.
    
  